111 related articles for article (PubMed ID: 37634562)
1. Cytochrome b561 regulates iron metabolism by activating the Akt/mTOR pathway to promote Breast Cancer Cells proliferation.
Zhou X; Guo X; Han J; Wang M; Liu Z; Ren D; Zhao J; Li Z
Exp Cell Res; 2023 Oct; 431(1):113760. PubMed ID: 37634562
[TBL] [Abstract][Full Text] [Related]
2. CKAP2L, transcriptionally inhibited by FOXP3, promotes breast carcinogenesis through the AKT/mTOR pathway.
Chi F; Chen L; Jin X; He G; Liu Z; Han S
Exp Cell Res; 2022 Mar; 412(2):113035. PubMed ID: 35065924
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
Lu PW; Li L; Wang F; Gu YT
J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
[TBL] [Abstract][Full Text] [Related]
4. HBXIP accelerates glycolysis and promotes cancer angiogenesis via AKT/mTOR pathway in bladder cancer.
Liu X; Li H; Che N; Zheng Y; Fan W; Li M; Li X; Xuan Y
Exp Mol Pathol; 2021 Aug; 121():104665. PubMed ID: 34216584
[TBL] [Abstract][Full Text] [Related]
5. SPOCK1/SIX1axis promotes breast cancer progression by activating AKT/mTOR signaling.
Xu M; Zhang X; Zhang S; Piao J; Yang Y; Wang X; Lin Z
Aging (Albany NY); 2020 Dec; 13(1):1032-1050. PubMed ID: 33293473
[TBL] [Abstract][Full Text] [Related]
6. Anti-Breast Cancer Potential of Quercetin via the Akt/AMPK/Mammalian Target of Rapamycin (mTOR) Signaling Cascade.
Rivera Rivera A; Castillo-Pichardo L; Gerena Y; Dharmawardhane S
PLoS One; 2016; 11(6):e0157251. PubMed ID: 27285995
[TBL] [Abstract][Full Text] [Related]
7. Gigantol inhibits proliferation and enhances DDP-induced apoptosis in breast-cancer cells by downregulating the PI3K/Akt/mTOR signaling pathway.
Huang J; Liu C; Duan S; Lin J; Luo Y; Tao S; Xing S; Zhang X; Du H; Wang H; Huang C; Wei G
Life Sci; 2021 Jun; 274():119354. PubMed ID: 33737087
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome b561 Serves as a Potential Prognostic Biomarker and Target for Breast Cancer.
Yang X; Zhao Y; Shao Q; Jiang G
Int J Gen Med; 2021; 14():10447-10464. PubMed ID: 35002301
[TBL] [Abstract][Full Text] [Related]
9. Expression and clinical prognostic value of CYB561 in breast cancer.
Zhou X; Shen G; Ren D; Guo X; Han J; Guo Q; Zhao F; Wang M; Dong Q; Li Z; Zhao J
J Cancer Res Clin Oncol; 2022 Aug; 148(8):1879-1892. PubMed ID: 35486183
[TBL] [Abstract][Full Text] [Related]
10. UBE2C affects breast cancer proliferation through the AKT/mTOR signaling pathway.
Lu ZN; Song J; Sun TH; Sun G
Chin Med J (Engl); 2021 Oct; 134(20):2465-2474. PubMed ID: 34620747
[TBL] [Abstract][Full Text] [Related]
11. FOXK1 promotes malignant progression of breast cancer by activating PI3K/AKT/mTOR signaling pathway.
Li ZQ; Qu M; Wan HX; Wang H; Deng Q; Zhang Y
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9978-9987. PubMed ID: 31799667
[TBL] [Abstract][Full Text] [Related]
12. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
[TBL] [Abstract][Full Text] [Related]
13. YBX1/lncRNA SBF2-AS1 interaction regulates proliferation and tamoxifen sensitivity via PI3K/AKT/MTOR signaling in breast cancer cells.
Hussain SA; Venkatesh T
Mol Biol Rep; 2023 Apr; 50(4):3413-3428. PubMed ID: 36754932
[TBL] [Abstract][Full Text] [Related]
14. Down-regulated microRNA-223 or elevated ZIC1 inhibits the development of pancreatic cancer via inhibiting PI3K/Akt/mTOR signaling pathway activation.
Zhu J; Lv J; Chen J; Zhang X; Ji Y
Cell Cycle; 2020 Nov; 19(21):2851-2865. PubMed ID: 33064959
[No Abstract] [Full Text] [Related]
15. LHX6 inhibits the proliferation, invasion and migration of breast cancer cells by modulating the PI3K/Akt/mTOR signaling pathway.
Bi QJ; Men XJ; Han R; Li GL
Eur Rev Med Pharmacol Sci; 2018 May; 22(10):3067-3073. PubMed ID: 29863252
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA CCAT2 reduces chemosensitivity to 5-fluorouracil in breast cancer cells by activating the mTOR axis.
Zhou D; Gu J; Wang Y; Luo B; Feng M; Wang X
J Cell Mol Med; 2022 Mar; 26(5):1392-1401. PubMed ID: 35170195
[TBL] [Abstract][Full Text] [Related]
18. MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway.
Li Z; Li C; Wu Q; Tu Y; Wang C; Yu X; Li B; Wang Z; Sun S; Sun S
Cell Death Dis; 2021 Jan; 12(1):97. PubMed ID: 33462219
[TBL] [Abstract][Full Text] [Related]
19. miR-660-5p promotes breast cancer progression through down-regulating TET2 and activating PI3K/AKT/mTOR signaling.
Peng B; Li C; He L; Tian M; Li X
Braz J Med Biol Res; 2020; 53(12):e9740. PubMed ID: 33146288
[TBL] [Abstract][Full Text] [Related]
20. The cancer-testis antigen a-kinase anchor protein 3 facilitates breast cancer progression via activation of the PTEN/PI3K/AKT/mTOR signaling.
Zhan CH; Ding DS; Zhang W; Wang HL; Mao ZY; Liu GJ
Bioengineered; 2022 Apr; 13(4):8478-8489. PubMed ID: 35322748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
